血清HBsAg和HBcrAg动力学在HBeAg阴性慢性乙型肝炎患者接受聚乙

StephenW

Clin Microbiol Infect. 2017 Jul 24. pii: S1198-743X(17)30387-7. doi: 10.1016/j.cmi.2017.07.016. [Epub ahead of print]
Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy.Chuaypen N1, Posuwan N2, Chittmittraprap S1, Hirankarn N3, Treeprasertsuk S4, Tanaka Y5, Shinkai N5, Poovorawan Y2, Tangkijvanich P6.
Author information
1Research Unit of Hepatitis and Liver Cancers, Chulalongkorn University, Bangkok, Thailand.2Center of Excellence in Clinical Virology, Chulalongkorn University, Bangkok, Thailand.3Immunology Unit, Department of Microbiology, Chulalongkorn University, Bangkok, Thailand.4Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.5Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.6Research Unit of Hepatitis and Liver Cancers, Chulalongkorn University, Bangkok, Thailand. Electronic address: [email protected].

AbstractOBJECTIVES: To investigate the role of serum hepatitis B core-related antigen (HBcrAg) kinetics in predicting long-term outcome of pegylated interferon (PEG-IFN)-based therapy in patients with HBeAg-negative chronic hepatitis B (CHB).
METHODS: 121 Thai patients with HBeAg-negative CHB recruited from a previous randomized trial of 48-week PEG-IFN alone or combined with entecavir were enrolled. HBsAg and HBcrAg levels were serially examined. Paired biopsies at baseline and post-treatment were assessed for intrahepatic cccDNA.
RESULTS: Persistent virological remission (PVR, defined by persistent HBV DNA <2,000 IU/mL), and HBsAg clearance at 3-year post-treatment were 29% (35/121) and 9% (11/121), respectively. Baseline HBcrAg correlated with HBV DNA and cccDNA but not with HBsAg. Baseline HBsAg, as well as HBsAg and HBcrAg declines were associated with PVR, while HBsAg decline was predictive of HBsAg clearance. High baseline antigen levels (HBsAg ≥3.4 log10 IU/mL plus HBcrAg ≥ 3.7 log10 U/mL) yielded high negative predictive values (NPVs) of PVR (45/50; 90%) and HBsAg clearance (50/50; 100%). At week 12, declines of HBsAg, HBcrAg and combined both antigens levels <0.5 log10 yielded NPVs for PVR of 90% (71/79), 82% (61/74) and 96% (48/50), respectively.
CONCLUSIONS: Quantitative HBcrAg was significantly associated with cccDNA in HBeAg-negative CHB. This novel antigen, together with HBsAg, could identify patients with low probability of PVR and HBsAg clearance in long-term follow-up.


Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.



KEYWORDS: Chronic hepatitis B; HBcrAg; HBsAg; Hepatitis B core-related antigen; Hepatitis B virus; cccDNA; pegylated interferon; predictor; stopping rule; treatment response

PMID:28750917DOI:10.1016/j.cmi.2017.07.016

• 
  


• 
  

StephenW

临床微生物感染2017 Jul 24. pii：S1198-743X（17）30387-7。 Doi：10.1016 / j.cmi.2017.07.016。 [提前印刷]
血清HBsAg和HBcrAg动力学在HBeAg阴性慢性乙型肝炎患者接受聚乙二醇干扰素治疗的预测作用。
Chuaypen N1，Posuwan N2，Chittmittraprap S1，Hirankarn N3，Treeprasertsuk S4，Tanaka Y5，Shinkai N5，Poovorawan Y2，Tangkijvanich P6。
作者信息

1
X-45454545 X-4545 X- 20045 X- 200新新新新新新新新旗新新旗新新新200新新新新旗新新旗新新200新新新新新新新新200新新，
2
泰国曼谷朱拉隆功大学临床病毒学卓越中心。
3
泰国曼谷朱拉隆功大学微生物学系免疫学单位。
4
泰国曼谷朱拉隆功大学医学系胃肠病学系。
五
X-45454545 X-4545 X- 20045 X- 20045 X- 20045 X- 20045 X- 20045 X- 20045 X- 20045 X- 20045 X-
6
X-45454545 X-4545 X- 20045 X- 200新新新新新新新新旗新新旗新新新200新新新新旗新新旗新新200新新新新新新新新200新新，电子地址：[email protected]。

抽象
目的：

调查血清乙型肝炎核心相关抗原（HBcrAg）动力学预测HBeAg阴性慢性乙型肝炎（CHB）患者聚乙二醇干扰素（PEG-IFN）治疗长期疗效的影响。
尿：

121名HBeAg阴性患者/
结果：

持续性病毒学缓解（PVR，持续性HBV DNA定义为<2000 IU / mL），三年治疗后HBsAg清除率分别为29％（35/121）和9％（11/121）。 HBsAg基因HBcrA。 HBsAg和HBcA（50/50; 100％）。 X-45454545 X- 20045 X- 20045 X- 20045 X- 20045 X- 20045 X- 20045 X- 20045 X- 20045 X- 0.5log10产生PVR的NPV分别为90％（71/79），82％（61/74）和96％（48/50）。
结论：

定量HBcrAg与HBeAg阴性CHB中的cccDNA显着相关。这种新型抗原与HBsAg一起可以识别长期随访中PVR和HBsAg清除概率较低的患者。

版权所有©2017欧洲临床微生物与传染病学会。发布者Elsevier Ltd.保留所有权利。
关键词：

目的探讨乙型肝炎病毒对慢性阻塞性肺疾病（CHD）患者乙型肝炎病毒（HBV）表达的影响。

结论：
28750917
DOI：
10.1016 / j.cmi.2017.07.016

antiHBVren

摘要：目的探讨血清乙肝核心相关抗原（HBcrAg）动力学预测HBeAg阴性慢性乙型肝炎（CHB）患者聚乙二醇干扰素（PEG-IFN）治疗长期疗效的作用。
方法：从以前的48周PEG-IFN单独或联合恩替卡韦随机试验招募的121名泰式HBeAg阴性CHB患者入组。连续检测HBsAg和HBcrAg水平。评估基线和治疗后的配对活组织检查肝内cccDNA。
结果：持续性病毒学缓解（PVR，由持续HBV DNA定义为<2,000 IU / mL）和3年治疗后HBsAg清除率分别为29％（35/121）和9％（11/121）。基线HBcrAg与HBV DNA和cccDNA相关，但与HBsAg无关。基线HBsAg以及HBsAg和HBcrAg下降与PVR相关，而HBsAg下降则预测HBsAg清除率。高基线抗原水平（HBsAg≥3.4log10 IU / mL加HBcrAg≥3.7 log10 U / mL）产生PVR（45/50; 90％）和HBsAg清除率（50/50; 100％）的高阴性预测值（NPV） 。在第12周，HBsAg，HBcrAg的下降和两种抗原水平<0.5log10的组合，PVR的NPV分别为90％（71/79），82％（61/74）和96％（48/50）。
结论：HBeAg阴性CHB中的定量HBcrAg与cccDNA显着相关。这种新型抗原与HBsAg一起可以识别长期随访中PVR和HBsAg清除概率较低的患者。